0001209191-23-024820.txt : 20230419
0001209191-23-024820.hdr.sgml : 20230419
20230419160725
ACCESSION NUMBER: 0001209191-23-024820
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230418
FILED AS OF DATE: 20230419
DATE AS OF CHANGE: 20230419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chu Yu-Waye
CENTRAL INDEX KEY: 0001854586
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36076
FILM NUMBER: 23830111
MAIL ADDRESS:
STREET 1: FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT STE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FATE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001434316
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 651311552
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12278 SCRIPPS SUMMIT DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92131
BUSINESS PHONE: 858.875.1803
MAIL ADDRESS:
STREET 1: 12278 SCRIPPS SUMMIT DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92131
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-18
0
0001434316
FATE THERAPEUTICS INC
FATE
0001854586
Chu Yu-Waye
C/O FATE THERAPEUTICS, INC.
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO
CA
92131
0
1
0
0
Chief Medical Officer
1
Common Stock
2023-04-18
4
S
0
215
6.52
D
142993
D
Common Stock
2023-04-18
4
S
0
2317
6.58
D
140676
D
Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the Reporting Person on April 15, 2019. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.
Represents the weighted average sale price of the shares sold from $6.46 to $6.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2-3.
Represents the weighted average sale price of the shares sold from $6.56 to $6.60 per share.
/s/ Cindy Tahl, as Attorney-in-Fact
2023-04-19